Stockreport

Altimmune: Don't Buy The GLP-1 Move-Up [Seeking Alpha]

Viking Therapeutics, Inc.  (VKTX) 
Last viking therapeutics, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vikingtherapeutics.com
PDF Altimmune's pipeline is young and faces strong competition in the GLP-1 market, as well as challenges in the NASH space. Shareholder dilution is another tangible risk [Read more]